Stevanato Group makes and sells pharmaceutical packaging and drug delivery products — primarily glass containers like pre-filled syringes, vials, and cartridges — to pharmaceutical and biotech companies globally. These containers hold injectable drugs, including biologics, vaccines, insulin, and GLP-1 therapies, until they reach the patient. Stevanato operates through two segments: Biopharmaceutical and Diagnostic Solutions (BDS, ~88% of revenue), which makes drug containment products and delivery devices, and Engineering (~12% of revenue), which makes pharmaceutical production equipment for in-house use and third-party customers. Stevanato's core growth driver is its "high-value solutions" (HVS) — premium, ready-to-use glass containers that arrive pre-sterilized and packaged for immediate use — which now account for roughly 46% of revenue. Key HVS product lines include EZ-fill (ready-to-use syringes, vials, and cartridges), Nexa (high-resistance containers for autoinjectors and GLP-1 drugs), and Alba (plasma-coated containers for sensitive biologics). Because drug containers are embedded in regulatory filings for drug approvals, switching suppliers requires a regulatory amendment, making customer relationships highly sticky and generating recurring revenue over the full commercial life of a drug. Stevanato is actively expanding capacity at new plants in Fishers, Indiana and Latina, Italy, targeting HVS demand from biologics and GLP-1 customers. The company also sells proprietary pen injectors and autoinjectors, positioning itself as an integrated provider of both containment and delivery.